Skip to main content
Delfa

← All trials/NCT07513168

RecruitingPhase 4

Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults

Efficacy and Safety of Low-Dose Semaglutide for Weight Loss and Cardiometabolic Improvement in Obese Pakistani Adults Without Type 2 Diabetes: A Single-Arm Open-Label Single-Center Trial

Asset

Semaglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

1

Estimated enrollment

60

Study population

Obesity / overweight

Eligibility highlights

•BMI ≥27.5•HbA1c ≤6.5%

Primary endpoint

•Body weight, % change

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07513168
Org study IDAIMS/ERC/9856/26

Timeline

Milestones

Study start2025-08-01actual
Study first posted2026-04-06actual
Last update posted2026-04-06actual
Primary completion2026-08-30estimated
Study completion2026-12-01estimated

Assets

Investigational agents

Semaglutide

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Adults aged 18 years or older.
•Body mass index (BMI ≥ 27.5 kg/m²) according to WHO Asian cut-offs.
•No diagnosis of type 2 diabetes mellitus, confirmed by:

Fasting blood glucose < 126 mg/dL, and HbA1c < 6.5% within three months prior to enrollment.

•Willingness and ability to provide written informed consent.
•Willingness to comply with study procedures, including weekly injections and lifestyle counseling.

Exclusion criteria

•History of pancreatitis.
•History or presence of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2).
•Pregnant or lactating women.
•Severe renal impairment (eGFR < 30 mL/min/1.73 m²) or hepatic impairment (ALT or AST > 3× upper limit of normal).
•Current use of other anti-obesity medications.
•Known hypersensitivity to semaglutide or any component of the formulation.
•Any condition that, in the investigator's opinion, would interfere with participation, adherence, or safety in the study.

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
3
MASH / liver
1
Cardiometabolic biomarkers
1
Safety / tolerability / PK
1

Weight & body composition

3 endpoints
Primary/protocol endpoint

Percentage Change in Body Weight

Time frame:Baseline to 24 weeks

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Change in Body Mass Index (BMI)

Time frame:Baseline, 12 weeks, and 24 weeks

BMI, change

change from baseline, improvement

Secondary/protocol endpoint

Change in Waist Circumference

Time frame:Baseline, 12 weeks, and 24 weeks

Waist circumference, change

change from baseline, improvement

MASH / liver

1 endpoint
Secondary/protocol endpoint

Change in Liver Enzymes

Time frame:Baseline, 12 weeks, and 24 weeks

change from baseline, improvement

componentsALT, change, AST, change

Cardiometabolic biomarkers

1 endpoint
Secondary/protocol endpoint

Change in Lipid Profile

Time frame:Baseline, 12 weeks, and 24 weeks

change from baseline, improvement

Safety / tolerability / PK

1 endpoint
Secondary/protocol endpoint

Safety and Adverse Drug Reactions

Time frame:Continous throughout 24 weeks

Treatment-emergent AEs (any)

descriptive

Publications (21)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.